(Q36580586)

15 August 2017

1 reference

title

Present and future of lung cancer vaccines (English)

1 reference

15 August 2017

Luis E Raez

1

1 reference

PubMed ID

16939384

15 August 2017

Joseph D Rosenblatt

series ordinal

2

1 reference

PubMed ID

16939384

15 August 2017

Eckhard R Podack

series ordinal

3

1 reference

PubMed ID

16939384

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Emerging Drugs

15 August 2017

1 reference

15 August 2017

11

1 reference

15 August 2017

3

1 reference

15 August 2017

445-459

1 reference

Cancer vaccines for the treatment and prevention of non small-cell lung cancer

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Lung cancer death rates in lifelong nonsmokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Revisions in the International System for Staging Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Docetaxel Versus Docetaxel/Cisplatin in Patients with Advanced Non–Small-Cell Lung Cancer: Preliminary Analysis of a Multicenter, Randomized Phase III Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Platin or no platin? That is the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation ofin vitro studies with clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Autologous dendritic cell vaccines for non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Lung cancer vaccines and gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Heat, heat shock, heat shock proteins and death: a central link in innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Origin, maturation and antigen presenting function of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.445

10.1517/14728214.11.3.445

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bgfzdfkgmbe2texl6egea5ttxa

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_bgfzdfkgmbe2texl6egea5ttxa

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bgfzdfkgmbe2texl6egea5ttxa

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/bgfzdfkgmbe2texl6egea5ttxa